Skip to main content
WRBYWarby Parker Inc.Sell4.4·$26.54+0.30%
Open full analysis

Warby Parker Inc. (WRBY) Stock Analysis

Breakout setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Analyst target reached at $26.54 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.4/10.

Warby Parker sells prescription eyewear, contact lenses, and vision care services through 323 retail stores and digital commerce, with unified pricing starting at $95 including prescription lenses. It employs ~4,000 people and operates two in-house optical labs. Contacts... Read more

$26.54+11.6% A.UpsideScore 4.4/10#23 of 26 Medical Instruments & Supplies
QualityF-score7 / 9FCF yield0.99%
Stop $24.67Target $29.60(resistance)A.R:R -0.1:1
Analyst target$29.92+12.7%12 analysts
$29.60our TP
$26.54price
$29.92mean
$24
$35

Sell if holding. Analyst target reached at $26.54 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.4/10. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 4.4/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202652d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Analyst target reached - limited upside remaining
Weak overall score: 4.4/10
Weak growth

Key Metrics

P/E (TTM)2646.0
P/E (Fwd)39.8
Mkt Cap$3.2B
EV/EBITDA69.3
Profit Mgn0.2%
ROE0.4%
Rev Growth8.3%
Beta1.97
DividendNone
Rating analysts20

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C1.71bearish
IV88%elevated
Max Pain$14-47.2% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.1
Revenue Growth
4.6

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
2.8
Quality Rank
3.2
Growth Rank
3.8

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
GatesA.R:R -0.1=NEGATIVEMomentum 6.8>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 52d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
56 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $22.12Resistance $30.20

Price Targets

$25
$30
A.Upside+11.5%
A.R:R-0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-1.9% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-06 (52d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WRBY stock a buy right now?

Sell if holding. Analyst target reached at $26.54 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.4/10. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $24.67. Score 4.4/10, moderate confidence.

What is the WRBY stock price target?

Take-profit target: $29.60 (+11.6% upside). Prior stop was $24.67. Stop-loss: $24.67.

What are the risks of investing in WRBY?

Analyst target reached - limited upside remaining; Weak overall score: 4.4/10; Weak growth.

Is WRBY overvalued or undervalued?

Warby Parker Inc. trades at a P/E of 2646.0 (forward 39.8). TrendMatrix value score: 5.2/10. Verdict: Sell.

What do analysts say about WRBY?

20 analysts cover WRBY with a consensus score of 4.0/5. Average price target: $30.

What does Warby Parker Inc. do?Warby Parker sells prescription eyewear, contact lenses, and vision care services through 323 retail stores and digital...

Warby Parker sells prescription eyewear, contact lenses, and vision care services through 323 retail stores and digital commerce, with unified pricing starting at $95 including prescription lenses. It employs ~4,000 people and operates two in-house optical labs. Contacts contributed 11.1% and eye exams 6.4% of 2025 net revenue, with glasses comprising the substantial majority.

Related stocks: NVST (Envista Holdings Corporation) · WST (West Pharmaceutical Services, I) · RMD (ResMed Inc.) · LMAT (LeMaitre Vascular, Inc.) · MMED (MiniMed Group, Inc.)
Home Stocks WRBY

Latest news

Latest News

StockStory48d ago
MSN41d ago
Newser41d ago
Yahoo Finance39d ago
MSN39d ago
TipRanks39d ago
Marketscreener.com39d agoEarnings
Marketscreener.com39d agoEarnings
IndexBox43d ago
The Globe and Mail44d agoAnalyst
MarketBeat45d agoAnalyst
Cantech Letter49d ago
TradingView42d ago
Insider Monkey39d ago
Yahoo Finance39d ago
Yahoo Finance39d agoEarnings
Investing.com India45d agoAnalyst
Yahoo Finance45d agoProduct
Benzinga13d agoProduct
Benzinga25d ago